Cancer stem cells, which share many common properties and regulatory machineries with normal stem cells, have recently been proposed to be responsible for tumorigenesis and to contribute to cancer resistance 1 . The main challenges in cancer biology are to identify cancer stem cells and to define the molecular events required for transforming normal cells to cancer stem cells. Here we show that Pten deletion in mouse haematopoietic stem cells leads to a myeloproliferative disorder, followed by acute T-lymphoblastic leukaemia (T-ALL). Self-renewable leukaemia stem cells (LSCs) are enriched in the c-Kit mid CD3 1 Lin 2 compartment, where unphosphorylated b-catenin is significantly increased. Conditional ablation of one allele of the b-catenin gene substantially decreases the incidence and delays the occurrence of T-ALL caused by Pten loss, indicating that activation of the b-catenin pathway may contribute to the formation or expansion of the LSC population. Moreover, a recurring chromosomal translocation, T(14;15), results in aberrant overexpression of the c-myc oncogene in c-Kit
Lin
2 LSCs and CD3 1 leukaemic blasts, recapitulating a subset of human T-ALL. No alterations in Notch1 signalling are detected in this model, suggesting that Pten inactivation and c-myc overexpression may substitute functionally for Notch1 abnormalities 2, 3 , leading to T-ALL development. Our study indicates that multiple genetic or molecular alterations contribute cooperatively to LSC transformation.
The PTEN-phosphatidylinositol-3-OH kinase (PI(3)K) pathway has been implicated in human leukaemogenesis 2, 4 . Although acute deletion of the murine Pten gene in adult haematopoietic stem cells (HSCs) leads to defects in HSC self-renewal, it also causes a brief myeloproliferative disorder (MPD), followed by the development of acute leukaemia 5, 6 . However, LSCs responsible for this transplantable disease have not been identified and, more significantly, the molecular mechanisms responsible for LSC formation remain to be elucidated.
Here we report the establishment of a new leukaemia model. In contrast to the Mx-1-Cre inducible system, in which Pten is deleted in nearly 100% of adult HSCs 5, 6 , Pten in this new model is conditionally deleted in 40% of fetal liver HSCs and their differentiated progeny (W.G. and H.W., unpublished observations) by the expression of the VE-cadherin-Cre (VEC-Cre) transgene 7 . VEC-Cre-mediated PTEN loss leads to a progressive development of MPD in the chronic phase followed by blast crisis. As early as one month after birth, mutant mice developed a myeloid shift with increased neutrophil counts (Fig. 1b, P30 , and Supplementary Fig. 1, CP) . One to two months later, mutant mice showed a marked increase in circulating neutrophils and white blood cells (Fig. 1b, P60-P90 ) and leukaemic blast invasion into haematopoietic and non-haematopoietic organs ( Supplementary Fig. 1, BC) . All mutant mice (n 5 266) died with hepatomegaly and splenomegaly, and 70% of them suffered from enlarged thymus and lymph nodes (Fig. 1a and data not shown) . By adopting CD45/side-scatter (CD45/SSC) fluorescence-activated cell sorting (FACS) analysis, a methodology used for the characterization of human leukaemic blasts 8 , we further identified two leukaemia subtypes (Fig. 1c) To understand the molecular and genetic mechanisms involved in LSC formation, we sought to identify the LSC population in our model. We first determined whether leukaemia development was transplantable and autonomous for Pten-null cells by transplanting 2 3 10 6 cells isolated from the bone marrow (BM), spleen or thymus of chronic-phase mutant male mice with the ROSA26-LacZ reporter gene 9 into sublethally irradiated mice with severe combined immunodeficiency disease (SCID) (Supplementary Fig. 2a ). Because both LacZ reporter activation and the Pten gene deletion are controlled by the same Cre transgene, LacZ expression, measurable by a b-galactosidase fluorescent substrate and FACS analysis (FACS-Gal), was used to mark Pten-null cells in this and subsequent experiments. Our results demonstrated that 90% of the recipient mice (n 5 22) developed leukaemia within three months after transplantation. Strikingly, more than 95% of leukaemic blasts in SCID recipients were LacZ 1 and Pten-null, and infiltrated into non-haematopoietic organs ( Supplementary Fig. 2b-d) , in a similar manner to the primary disease ( Supplementary Fig. 1 ). This result suggests that the leukaemia is initiated by donor-derived Pten-null LSCs.
LSCs have been reported to arise from HSCs 10, 11 or from myeloid and B-lineage progenitors 12, 13 . Our initial screening of several stemcell and progenitor markers identified a small c-Kit mid subgroup within the blast compartment ( Supplementary Fig. 2e ). When combined with CD3, a pan-T-cell marker, we further identified three major populations: CD3
2 , c-Kit
1 and c-Kit mid CD3 1 (Supplementary Fig. 3 ). We then sorted these three subpopulations from an individual leukaemic mouse and performed transplantation experiments with various numbers of sorted cells ( Fig. 2a and Supplementary Fig. 3 ). When 10 4 cKit 2 CD3 1 cells were transplanted into sublethally irradiated SCID mice, no leukaemia development was observed within 100 days, the longest time point we have followed for transplantation experiments. This is in sharp contrast with T-ALL development in those recipients transplanted with 10 (Fig. 2b and Supplementary Fig. 4c ). Although the same numbers of c-Kit mid CD3
1 Lin 2 cells were serially transplanted, disease latencies were significantly shortened from 64 days to 20 days (Fig. 2b) . Similar results were obtained when LacZ 1 c-Kit mid CD3
1 -derived BM cells were serially transplanted ( Supplementary Fig. 4a,  b) . Thus, similarly to a previous study of human LSCs 10 , LSCs in our model are self-renewable and give rise to a more accelerated disease through serial transplantations.
Because Pten deletion in HSCs results in a self-renewal defect and stem cell exhaustion 5, 6 (W.G., J.L. and H.W., unpublished observations), understanding the molecular mechanism involved in the selfrenewal acquisition of the c-Kit mid CD3 1 LSCs became the central focus of our study. The Wnt/b-catenin signalling pathway is known to be involved in the regulation of HSC self-renewal 15 , and its activation is required for the in vitro replating activity of the LSCs from myeloid blast crisis of human chronic myeloid leukaemia 13 .
CD3
1 blasts (Fig. 3a, b, Supplementary Figs 5 and 6c , and data not shown) and modest increases in the c-Kit high Lin 2 HSC/progenitor population in the blast-crisis mice (Fig. 3b ) and the CD3 2 CD4 2 CD8 2 T progenitors in the chronic-phase mice ( Supplementary Fig. 6b ). This result suggests that activation of b-catenin may be associated with LSC formation and T-ALL development.
To improve our understanding of the role of b-catenin in LSC formation, we took a genetic approach by simultaneously deleting the genes encoding PTEN and b-catenin (Pten and Ctnnb1, respectively) in HSCs. Fig. 7a, b) 
;VEC-Cre 1 (blue line; three independent experiments) and Pten loxP/loxP ;VEC-Cre 1 (green line; four independent experiments) mice. A gradient of leukaemogenic potential was observed in cells derived from different mutant haematopoietic organs (thymus . spleen . BM), which was consistent with the relative enrichment of LSCs in these organs. The occurrence of acute leukaemia and death were markedly decreased and delayed when one allele of Ctnnb1 was deleted from donor cells (Fig. 3c and Supplementary Fig. 7c ). These results suggest that dysregulated b-catenin activity may contribute to LSC formation and leukaemogenesis in our model.
Chromosomal translocations are frequently associated with human leukaemia and lymphoma. To investigate chromosomal abnormalities in our model, we employed cytogenetic approaches, including spectral karyotyping (SKY) and fluorescence in situ hybridization (FISH) analyses. SKY analysis revealed no recurrent structural abnormalities in BM cells from chronic-phase mutant or WT mice (Fig. 4d) . In contrast, all three blast-crisis samples we initially analysed showed the same T(14;15) chromosomal translocation in 9-61% of analysed metaphases (Fig. 4a, boxed chromosomes, and Fig. 4d) , which was reminiscent of leukaemic clonal expansion in humans. Of the cells carrying T(14;15), 53% contained two or even three copies of Der (15)T(14;15) (Fig. 4a, b) , suggesting a strong selective pressure in cells with this translocation and implying a possible role of translocation-associated genes in leukaemic transformation.
Because breakpoints in chromosomes 14 and 15 seemed to be located at 14qC2-C3 and 15qD3 (Fig. 4a) , we searched for translocation targets in the public domain and identified the T-cell antigen receptor (TCR)-a/d (Tcra/Tcrd) cluster on chromosome 14qC2 and c-myc on chromosome 15qD3 as potential candidates. A similar translocation of t (8;14) is known to be associated with a subset of human T-ALL 16 . Using two-colour FISH analysis with validated bacterial artificial chromosome (BAC) clones (Supplementary Fig. 8a) , we confirmed the translocation between Tcra/Tcrd and c-myc and narrowed down the breakpoints to two minimal regions (Fig. 4b, c , and Supplementary Fig. 8b ): a roughly 209,000-base-pair (209-kb) fragment containing the TRAC gene and the TRA enhancer and 680 kb between the genes Pvt1 and Tsg101-ps. The same translocation was found in four additional leukaemic recipients transplanted with primary chronic mutant cells or sorted LSCs (Fig. 4d and Supplementary Fig. 8c ), suggesting that T-ALL can be recapitulated at the genetic level and that the genomic abnormality is intrinsic to LSCs.
To determine whether c-myc expression was indeed altered by Tcra regulatory machinery, as reported for human T-ALL 17 , we quantified c-myc expression in BM and thymic cells with the use of quantitative RT-PCR and FACS analysis. Strikingly, c-myc expression was not changed in the chronic phase but was markedly increased in BM or thymic cells isolated from primary or transplanted blast-crisis mice (Fig. 4e) . Furthermore, c-myc overexpression was detected only in LSCs and CD3
1 blast cells but not in HSCs or CD3 2 cells (Fig. 4f and Supplementary Fig. 9a, b) . These results rule out a predominant role of the deregulated PTEN-PI(3)K-AKT pathway in c-myc overexpression and highlight the importance of overexpressed C-myc in the formation of CD3
1 LSCs and T-ALL development in our model. Our study provides strong evidence that the molecular and genetic events involved in 'multiple-hit' leukaemogenesis are likely to take place at the levels of HSCs and LSCs 18 . In this model, Pten inactivation in HSCs serves as the first hit to activate the PI(3)K-AKT pathway, conferring survival and proliferative advantages, and to promote genomic instability 19 , leading to additional alterations. Among them, activation of b-catenin may contribute to the acquisition of self-renewal capacity of LSCs, while the T(14;15) chromosomal translocation results in T-lineage-specific overexpression of c-myc, which may promote Pten-null LSC self-renewal and lead to T-ALL development. The sequential order of b-catenin activation and c-myc overexpression is currently unknown but it does not seem that c-Myc function is mediated by b-catenin signalling (Supplementary Fig. 9c, d) .
Dysregulated NOTCH1 signalling is involved in about 56% of human T-ALL 3 . However, in our leukaemia samples we detected no mutations in Notch1 heterodimerization (HD) domain and PEST domain, two mutation hot-spots associated with human T-ALL (Supplementary Fig. 10a) . Furthermore, neither a consistent decrease in Fbxw7 expression, a negative regulator of Notch signalling that is frequently altered in human T-ALL 2 , nor an increase in the expression of the NOTCH1 target gene Hes1 was detected in this model ( Supplementary Fig. 10b ). Given recent reports that the activated Notch1 signalling directly induces c-myc overexpression [20] [21] [22] and modulates Pten expression 23 , the T(14,15)-mediated c-myc overexpression and Pten deletion together may substitute functionally for Notch1 mutations, leading to T-ALL development in our model.
METHODS SUMMARY
Mice. Mice were maintained in the animal facility of University of California Los Angeles in accordance with federal and institutional guidelines and were used between 1 and 5 months of age unless otherwise noted. Pten loxP/loxP mice have been deposited to the Jackson Laboratory. Transplantation assay. Cells were directly collected from or sorted from BM, spleen or thymus, balanced with SCID carrier cells in some cases and transplanted into sublethally irradiated SCID recipients. Leukaemia was determined by CD45/SSC FACS, FACS-Gal and histological analyses. Flow cytometric (FACS) analysis. Haematopoietic cells were obtained by flushing femurs or smashing the spleen and thymus, and were then stained with antibodies. These cells were either analysed or sorted by flow cytometry. Lineage depletion was performed with microbeads (Miltenyi Biotec). FACSGal analysis was performed by fluorescein di-b-D-galactopyranoside loading and FACS analysis. To analyse activated b-catenin and c-Myc, cells were stained with surface markers, fixed, permeabilized and stained with corresponding antibodies for FACS analysis. Profiling and histology analysis of peripheral blood. Peripheral blood (PB) was collected, analysed for PB profile, spread for blood smears and stained with Giemsa stain or Giemsa-Wright (Fisher). Tissues dissected from killed mice were fixed, embedded in paraffin and sectioned for haematoxylin/eosin staining. Cytospin slides with single suspension cells were prepared for immunochemistry with antibodies. SKY and FISH analysis. Metaphases were prepared directly from BM cells in colcemid-treated mice for SKY assay and FISH analysis. Six murine DNA BAC clones were obtained, prepared, and validated for FISH analysis. RT-PCR. Total RNA was extracted and reverse-transcribed into complementary DNAs. These cDNAs were diluted for real-time RT-PCR with primers for the genes of interest and reference. C t was obtained for a statistical calculation of relative fold changes. For LSC identification, each of the three populations, as shown in Fig. 2b , was sorted from BM of blast-crisis mutants, serially diluted and balanced with Pten 1/1 carrier cells from SCID mice before being transplanted into sublethally irradiated SCID recipients. The relative fractions of these three populations varied from mouse to mouse. Leukaemia was determined by CD45/SSC FACS, FACS-Gal and histological analyses.
In serial transplantation assays, when a transplant recipient with 900 or 1,000 candidate LSCs (c-Kit
) developed leukaemia, the same number of LSCs sorted (Fig. 2c) or various numbers of BM cells harvested ( Supplementary  Fig. 4c ) from this recipient mouse were balanced with Pten 1/1 SCID carrier cells in most cases (indicated in the figure legends) and transplanted into secondary SCID recipients. The same procedure was repeated up to the fourth passage. Leukaemic blasts were analysed on CD45/SSC plots as described previously 8 . An abnormal blast population was detected in all mutant animals at blast crisis and constituted more than 20% of the total leukocytes (Fig. 1c) , satisfying the French-American-British (FAB) criteria for human acute leukaemia. The blast cells were Pten-null, large, immature and morphologically distinct from normal lineage cells but similar to human leukaemic blasts (Fig. 1c) . Leukaemia with blasts positive for CD3, CD4 and/or CD8 was considered T-ALL, whereas leukaemia with more than 3% of Gr-1 low Mac-1 1 blasts was AML. Blasts with both CD3 1 CD4 1 and Gr-1 low Mac-1 1 may be either a mixture of T-ALL and AML or T-ALL bearing myeloid markers 26 . Intracellular staining with an anti-b-catenin (unphosphorylated) mouse monoclonal antibody (clone 8E4; AXXORA or Millipore/Upstate), anti-c-myc rabbit polyclonal antibody (Cell Signaling Technology) or control mouse or rabbit IgG, followed by staining with donkey anti-mouse-FITC or anti-rabbit-FITC antibody (Jackson Immunoresearch Laboratories), was performed with the Fix & Perm Kit (Caltag) in accordance with the manufacturer's instructions. PB profiling and histology analysis. For PB profile analysis, 200 ml of PB was collected by retro-orbital bleeding and analysed on a HemaVet HV950FS (Drew
